platinum has been researched along with Carcinoma, Small Cell Lung in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.20) | 29.6817 |
| 2010's | 26 (31.33) | 24.3611 |
| 2020's | 56 (67.47) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Fujishita, T; Ito, K; Matsubara, T; Okamoto, T; Seto, T; Takamori, S; Toyozawa, R; Yamaguchi, M | 1 |
| Chi, X; He, M; Li, H; Shi, X; Sun, Y; Wang, B; Wang, L; Yang, X | 1 |
| Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Endoh, H; Fujita, A; Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kiyoshima, M; Kotake, M; Matsuguma, H; Minato, K; Minemura, H; Nakamura, Y; Sugiyama, T; Suzuki, H; Yamada, Y | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| Anderson, AKL; Ansell, P; Aparicio, A; Byers, LA; Byun, J; Cardnell, RJ; Fernandez, L; Fujimoto, J; Gay, CM; Gilbertson, C; He, L; Jendrisak, A; Jones, J; Negrao, MV; Novegil, V; Rocha, P; Schonhoft, JD; Solis Soto, LM; Stewart, CA; Tran, H; Wang, J; Wang, Q; Wang, R; Wang, WL; Wenstrup, R; Wistuba, II; Zhang, B; Zhang, J | 1 |
| An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H | 1 |
| Lin, A; Luo, P; Shen, W; Yao, Z; Yi, Y; Zhang, J | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
| Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F | 1 |
| Chen, LH; Du, Y; Ouyang, HF; Ti, XY; Wu, S; Xu, X; Zhang, Y | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY | 1 |
| Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD | 1 |
| Al-Hashami, Z; Ho, C; Leung, B; Rittberg, R | 1 |
| Jiang, A; Lin, A; Luo, P; Mou, W; Zhang, J; Zhu, L | 1 |
| Akerley, W; Haaland, B; Kerrigan, K; Patel, S; Puri, S; Sama, S; Sinnott, JA | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K | 1 |
| Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P | 1 |
| Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J | 1 |
| Adeyemi, A; Boccuti, A; Caisip, C; Hanvesakul, R; Jansen, JP; Naveh, N; Park, JE; Rengarajan, B; Wilson, FR | 1 |
| Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
| Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Abbar, B; Bergeret, S; Campedel, L; Foka Tichoue, H; Gougis, P; Hassani, L; Jaffrelot, L; Lassoued, D; Morardet, L; Perrier, A; Roussel-Simonin, C; Spano, JP; Taillade, L; Veyri, M; Vozy, A; Wassermann, J | 1 |
| Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY | 1 |
| Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J | 1 |
| Huang, Z; Li, D; Lin, L; Liu, Z; Zhang, G; Zhong, J; Zhuang, W | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Berta, J; Bogos, K; Döme, B; Ferencz, B; Fillinger, J; Horváth, L; Lantos, A; Megyesfalvi, Z; Rényi-Vámos, F | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
| Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y | 1 |
| Arulananda, S; John, T; Mitchell, P | 1 |
| Escriu, C; Sallam, M; Wong, H | 1 |
| Li, K; Lin, A; Luo, P; Wei, T; Zhang, J | 1 |
| Lee, SH; Park, K; Park, S | 1 |
| Ikeda, N; Kajiwara, N; Kudo, Y; Maehara, S; Matsubayashi, J; Minna, JD; Ohira, T; Otaki, Y; Shimada, Y | 1 |
| Arnold, SM; Baggstrom, MQ; Chansky, K; Crowley, JJ; Hamm, J; Leggas, M; Rosales, J; Sanborn, RE; Thompson, MA; Villano, JL; Waqar, SN; Willis, M | 1 |
| Balakrishnan, A; Kumar, P; Prasanna, BK | 1 |
| Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC | 1 |
| Ahn, JS; Ahn, MJ; Godin, RE; Hollingsworth, SJ; Jung, HA; Kim, HJ; Lee, SH; Mortimer, PGS; Park, K; Park, S; Park, WY; Shim, J; Smith, SA; Sun, JM | 1 |
| He, L; Huang, X; Li, Y; Lou, Y; Wang, L; Yang, H; Zhang, Y | 1 |
| Antonia, SJ; Boyle, TA; Chiappori, A; Conejo-Garcia, JR; Creelan, B; Dilling, TJ; Grass, GD; Gray, J; Haura, E; Karimi, AM; Kim, S; Lannon, A; Latifi, K; Li, J; MacMillan, G; Perez, BA; Powell, C; Rose, T; Rosenberg, S; Saller, J; Saltos, A; Schell, MJ; Shafique, M; Tanvetyanon, T; Wang, M | 1 |
| De Petris, L; Kanter, L; Lewensohn, R; Ortiz-Villalón, C; Tendler, S; Viktorsson, K | 1 |
| Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L | 1 |
| Ding, HY; Fang, L; Tong, YH; Xin, WX; Xu, GQ; Yang, GN; Zhang, B; Zhong, LK | 1 |
| Chen, B; Lin, J; Peng, J; Xue, L | 1 |
| Beaver, JA; Goldberg, KB; Kluetz, PG; Larkins, E; Li, X; Mathieu, L; Mishra-Kalyani, P; Pai-Scherf, L; Pazdur, R; Rodriguez, L; Shah, S; Singh, H; Theoret, MR; Vallejo, J | 1 |
| Bandyopadhyay, A; Behera, D; Sharma, S; Singh, N | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Chen, L; Tang, H; Wang, Y; Yang, N; Zhang, Y | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y | 1 |
| Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X | 1 |
| Aldrich, J; Barilla, H; Byron, SA; Carpten, JD; Craig, DW; Kiefer, JA; Sangal, A; Weiss, GJ; Whitsett, TG | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Cao, S; Jin, S; Meng, Q; Wang, C; Xu, S; Yu, Y | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Bara, RO; Byers, LA; Cardnell, RJ; Gay, CM; Heymach, JV; Johnson, FM; Ma, J; Sen, T; Su, X; Tong, P; Wakefield, C; Wang, J | 1 |
| Drapkin, BJ; Farago, AF; Galmarini, CM; Kahatt, C; Lopez-Vilarino de Ramos, JA; Núñez, R; Paz-Ares, L | 1 |
| Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y | 1 |
| Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P | 1 |
| Ahn, JS; Ahn, MJ; Lee, B; Lee, H; Lee, SH; Park, K; Park, S; Park, WY; Sun, JM | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Blackstock, AW; Bogart, JA; Crawford, J; Hodgson, L; Pang, H; Salama, JK; Schild, SE; Urbanic, JJ; Vokes, EE | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Ganti, AK; West, WW; Zhen, W | 1 |
| Feng, R; Luo, X; Xian, L; Yang, N; Yang, Y | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Kijima, T; Minami, T; Morio, K; Niki, K; Sozu, T; Uejima, E | 1 |
| Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
12 review(s) available for platinum and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | 2023 |
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States; United States Food and Drug Administration | 2021 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Current concepts in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2013 |
The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
Topics: Antineoplastic Agents; Databases, Factual; DNA-Binding Proteins; Endonucleases; Gene Expression Regulation, Neoplastic; Humans; Platinum; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2014 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
18 trial(s) available for platinum and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States | 2021 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Topics: Disease Progression; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligopeptides; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug-Related Side Effects and Adverse Reactions; Female; Gene Amplification; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Pyrimidinones; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2020 |
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nivolumab; Platinum; Progression-Free Survival; Prospective Studies; Small Cell Lung Carcinoma; Thorax | 2021 |
The efficacy of music therapy to relieve pain, anxiety, and promote sleep quality, in patients with small cell lung cancer receiving platinum-based chemotherapy.
Topics: Anxiety; Humans; Lung Neoplasms; Music Therapy; Pain; Platinum; Sleep; Small Cell Lung Carcinoma | 2021 |
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
Topics: Adult; Aged; Biopsy; Exome; Female; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Male; Middle Aged; Neoplasm Proteins; Pilot Projects; Platinum; Sequence Alignment; Sequence Analysis, RNA; Small Cell Lung Carcinoma; Transcriptome; Treatment Outcome | 2017 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbolines; Cyclophosphamide; Doxorubicin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Platinum; Progression-Free Survival; Small Cell Lung Carcinoma; Topotecan; Tumor Microenvironment; Vincristine | 2019 |
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Radiotherapy Dosage; Small Cell Lung Carcinoma | 2013 |
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil | 2016 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
53 other study(ies) available for platinum and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Platinum; Small Cell Lung Carcinoma | 2021 |
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Topics: Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; DNA; Humans; Lung Neoplasms; Neoplastic Cells, Circulating; Nuclear Proteins; Platinum; Small Cell Lung Carcinoma | 2022 |
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.
Topics: Cisplatin; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment | 2022 |
Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Homologous Recombination; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Topics: Aged; Female; Humans; Lung Neoplasms; Male; Patient Acceptance of Health Care; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Activation of the TGF-
Topics: Carcinoma, Small Cell; Humans; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2022 |
Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma | 2023 |
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2023 |
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
[Small cell lung cancer heterogeneity and molecular subtypes: biological and clinical relevance].
Topics: Clinical Relevance; Humans; Immunotherapy; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?
Topics: DNA Damage; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom | 2019 |
DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
Topics: Cisplatin; DNA Damage; Exome; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
Topics: Cisplatin; DNA Damage; Exome; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Small Cell Lung Carcinoma | 2019 |
Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Extracellular Vesicles; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Platinum; Prognosis; Small Cell Lung Carcinoma; Ubiquitin Thiolesterase; Up-Regulation | 2020 |
Circulating tumor cell clusters and circulating tumor cell-derived explant models as a tool for treatment response.
Topics: Animals; Antineoplastic Agents; Blood Cells; Disease Progression; Etoposide; Humans; Mice, Nude; Neoplastic Cells, Circulating; Platinum; Small Cell Lung Carcinoma | 2020 |
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Topics: Ankyrins; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Small Cell Lung Carcinoma; Tyrosine | 2020 |
The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Platinum; Prognosis; Receptor, Notch1; Small Cell Lung Carcinoma; Survival Analysis; Transcription Factor HES-1; Treatment Outcome | 2020 |
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Etoposide; Female; Humans; Male; Markov Chains; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prospective Studies; Small Cell Lung Carcinoma | 2021 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nutrition Assessment; Platinum; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2018 |
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Aurora Kinase A; Cisplatin; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Small Cell Lung Carcinoma; Software | 2019 |
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
Topics: Adult; Aged; Aged, 80 and over; DNA Damage; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Small Cell Lung Carcinoma; Tumor Burden | 2019 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome; Weight Loss | 2016 |
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2009 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |